Immunovant, Inc.
IMVT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -1.96 | -0.52 | 0.39 | -3.03 |
| FCF Yield | -3.66% | -4.29% | -4.28% | -2.76% |
| EV / EBITDA | -18.10 | -16.80 | -16.50 | -28.59 |
| Quality | ||||
| ROIC | -25.47% | -21.07% | -16.18% | -32.46% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.81 | 0.97 | 1.04 | 0.90 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 12.69% | -5.93% | -10.21% | -13.20% |
| Safety | ||||
| Net Debt / EBITDA | 4.15 | 4.71 | 6.28 | 3.28 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -5,928.00 | 0.00 | 0.00 | 0.00 |